Cargando…

Drug repurposing for the treatment of COVID-19

Coronavirus disease 2019 (COVID-19) remains prevalent worldwide since its onset was confirmed in Wuhan, China in 2019. Vaccines against the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have shown a preventive effect against the onset and severity of COVID-19, and so...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Yuri, Nishiyama, Kazuhiro, Nishimura, Akiyuki, Noda, Takamasa, Okabe, Kaori, Kusakabe, Takahiro, Kanda, Yasunari, Nishida, Motohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040495/
https://www.ncbi.nlm.nih.gov/pubmed/35641023
http://dx.doi.org/10.1016/j.jphs.2022.04.007
_version_ 1784694349425016832
author Kato, Yuri
Nishiyama, Kazuhiro
Nishimura, Akiyuki
Noda, Takamasa
Okabe, Kaori
Kusakabe, Takahiro
Kanda, Yasunari
Nishida, Motohiro
author_facet Kato, Yuri
Nishiyama, Kazuhiro
Nishimura, Akiyuki
Noda, Takamasa
Okabe, Kaori
Kusakabe, Takahiro
Kanda, Yasunari
Nishida, Motohiro
author_sort Kato, Yuri
collection PubMed
description Coronavirus disease 2019 (COVID-19) remains prevalent worldwide since its onset was confirmed in Wuhan, China in 2019. Vaccines against the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have shown a preventive effect against the onset and severity of COVID-19, and social and economic activities are gradually recovering. However, the presence of vaccine-resistant variants has been reported, and the development of therapeutic agents for patients with severe COVID-19 and related sequelae remains urgent. Drug repurposing, also called drug repositioning or eco-pharma, is the strategy of using previously approved and safe drugs for a therapeutic indication that is different from their original indication. The risk of severe COVID-19 and mortality increases with advancing age, cardiovascular disease, hypertension, diabetes, and cancer. We have reported three protein–protein interactions that are related to heart failure, and recently identified that one mechanism increases the risk of SARS-CoV-2 infection in mammalian cells. This review outlines the global efforts and outcomes of drug repurposing research for the treatment of severe COVID-19. It also discusses our recent finding of a new protein–protein interaction that is common to COVID-19 aggravation and heart failure.
format Online
Article
Text
id pubmed-9040495
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
record_format MEDLINE/PubMed
spelling pubmed-90404952022-04-26 Drug repurposing for the treatment of COVID-19 Kato, Yuri Nishiyama, Kazuhiro Nishimura, Akiyuki Noda, Takamasa Okabe, Kaori Kusakabe, Takahiro Kanda, Yasunari Nishida, Motohiro J Pharmacol Sci Review Coronavirus disease 2019 (COVID-19) remains prevalent worldwide since its onset was confirmed in Wuhan, China in 2019. Vaccines against the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have shown a preventive effect against the onset and severity of COVID-19, and social and economic activities are gradually recovering. However, the presence of vaccine-resistant variants has been reported, and the development of therapeutic agents for patients with severe COVID-19 and related sequelae remains urgent. Drug repurposing, also called drug repositioning or eco-pharma, is the strategy of using previously approved and safe drugs for a therapeutic indication that is different from their original indication. The risk of severe COVID-19 and mortality increases with advancing age, cardiovascular disease, hypertension, diabetes, and cancer. We have reported three protein–protein interactions that are related to heart failure, and recently identified that one mechanism increases the risk of SARS-CoV-2 infection in mammalian cells. This review outlines the global efforts and outcomes of drug repurposing research for the treatment of severe COVID-19. It also discusses our recent finding of a new protein–protein interaction that is common to COVID-19 aggravation and heart failure. The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. 2022-07 2022-04-25 /pmc/articles/PMC9040495/ /pubmed/35641023 http://dx.doi.org/10.1016/j.jphs.2022.04.007 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Kato, Yuri
Nishiyama, Kazuhiro
Nishimura, Akiyuki
Noda, Takamasa
Okabe, Kaori
Kusakabe, Takahiro
Kanda, Yasunari
Nishida, Motohiro
Drug repurposing for the treatment of COVID-19
title Drug repurposing for the treatment of COVID-19
title_full Drug repurposing for the treatment of COVID-19
title_fullStr Drug repurposing for the treatment of COVID-19
title_full_unstemmed Drug repurposing for the treatment of COVID-19
title_short Drug repurposing for the treatment of COVID-19
title_sort drug repurposing for the treatment of covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040495/
https://www.ncbi.nlm.nih.gov/pubmed/35641023
http://dx.doi.org/10.1016/j.jphs.2022.04.007
work_keys_str_mv AT katoyuri drugrepurposingforthetreatmentofcovid19
AT nishiyamakazuhiro drugrepurposingforthetreatmentofcovid19
AT nishimuraakiyuki drugrepurposingforthetreatmentofcovid19
AT nodatakamasa drugrepurposingforthetreatmentofcovid19
AT okabekaori drugrepurposingforthetreatmentofcovid19
AT kusakabetakahiro drugrepurposingforthetreatmentofcovid19
AT kandayasunari drugrepurposingforthetreatmentofcovid19
AT nishidamotohiro drugrepurposingforthetreatmentofcovid19